Compare IQV & PEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IQV | PEG |
|---|---|---|
| Founded | 1982 | 1903 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1B | 37.0B |
| IPO Year | 2013 | 1994 |
| Metric | IQV | PEG |
|---|---|---|
| Price | $260.43 | $71.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 22 |
| Target Price | ★ $286.79 | $85.31 |
| AVG Volume (30 Days) | 1.3M | ★ 2.9M |
| Earning Date | 10-27-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 3.90% |
| EPS Growth | 4.67 | ★ 19.21 |
| EPS | 1.61 | ★ 2.15 |
| Revenue | $9,739,000,000.00 | ★ $12,168,000,000.00 |
| Revenue This Year | $6.79 | $5.57 |
| Revenue Next Year | $6.07 | $2.45 |
| P/E Ratio | $164.98 | ★ $31.87 |
| Revenue Growth | ★ 41.60 | 18.25 |
| 52 Week Low | $154.50 | $66.15 |
| 52 Week High | $277.40 | $87.63 |
| Indicator | IQV | PEG |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 55.22 |
| Support Level | $252.53 | N/A |
| Resistance Level | $274.60 | $74.65 |
| Average True Range (ATR) | 7.27 | 1.17 |
| MACD | -1.99 | 0.35 |
| Stochastic Oscillator | 14.24 | 97.71 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and PSEG Power, which owns all or a share of three nuclear plants and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system under a contract extension through 2030. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.